Xia Li 1,2 , Ting Zhong 1,2 , Rong Tang 1,2 , Chao Wu 1,2 , Yuting Xie 1,2 , Fang Liu 1,2 , Zhiguang Zhou 1,2 Show Affiliations »
Abstract
CONTEXT: Partial remission (PR) in type 1 diabetes (T1D) is accompanied by downregulation of the immune response. Programmed cell death-1 (PD-1) and its ligand (PD-L1) are important immunosuppressive molecules, but their changes in the PR phase are unclear. OBJECTIVE: We investigated the dynamic changes of PD-1/PD-L1 expression on T cells around the PR phase in T1D. METHODS: Ninety-eight T1D patients were recruited cross-sectionally and grouped according to PR status into nonremitters (individuals who did not undergo PR during the disease course; n = 39), pre-PR (n = 15), mid-PR (n = 30), and post-PR (n = 14) subgroups. PR was defined according to C-peptide level ≥300 pmol/L or index of insulin-adjusted hemoglobin A1c ≤9 as recommended. Among all the 98 patients, 29 newly diagnosed individuals were prospectively followed up for 1 year. The dynamic changes of PD-1/PD-L1 expression, frequency of regulatory T cells (Tregs) and IL-35+ Tregs among peripheral CD4/CD8+ T cells were determined. RESULTS: PD-1/PD-L1 on CD4+/CD8+ T cells showed a dynamic change around the PR phase: lowest in pre-PR phase, restored in mid-PR phase, and declined again in post-PR phase. Conversely, this pattern did not occur for nonremitters. Notably, PD-1 expression on CD8+ T cells in mid-PR was positively correlated with the length of the PR phase. The percentages of circulating Tregs and IL-35+ Tregs showed no relation to PR. CONCLUSIONS: The PR phase is associated with restoration of PD-1/PD-L1 on CD4+ and CD8+ T cells, suggesting that PD-1/PD-L1 may be a potential target for prolonging this phase in T1D. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CONTEXT: Partial remission (PR) in type 1 diabetes (T1D) is accompanied by downregulation of the immune response. Programmed cell death-1 (PD-1 ) and its ligand (PD-L1 ) are important immunosuppressive molecules, but their changes in the PR phase are unclear. OBJECTIVE: We investigated the dynamic changes of PD-1 /PD-L1 expression on T cells around the PR phase in T1D. METHODS: Ninety-eight T1D patients were recruited cross-sectionally and grouped according to PR status into nonremitters (individuals who did not undergo PR during the disease course; n = 39), pre-PR (n = 15), mid-PR (n = 30), and post-PR (n = 14) subgroups. PR was defined according to C-peptide level ≥300 pmol/L or index of insulin -adjusted hemoglobin A1c ≤9 as recommended. Among all the 98 patients , 29 newly diagnosed individuals were prospectively followed up for 1 year. The dynamic changes of PD-1 /PD-L1 expression, frequency of regulatory T cells (Tregs) and IL-35+ Tregs among peripheral CD4 /CD8 + T cells were determined. RESULTS: PD-1 /PD-L1 on CD4 +/CD8 + T cells showed a dynamic change around the PR phase: lowest in pre-PR phase, restored in mid-PR phase, and declined again in post-PR phase. Conversely, this pattern did not occur for nonremitters. Notably, PD-1 expression on CD8 + T cells in mid-PR was positively correlated with the length of the PR phase. The percentages of circulating Tregs and IL-35+ Tregs showed no relation to PR. CONCLUSIONS: The PR phase is associated with restoration of PD-1 /PD-L1 on CD4 + and CD8 + T cells, suggesting that PD-1 /PD-L1 may be a potential target for prolonging this phase in T1D. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Disease
Gene
Species
Keywords:
PD-1; PD-L1; T cell subsets; partial remission phase; type 1 diabetes
Mesh： See more »
Substances： See more »
Year: 2020
PMID： 32236416 DOI： 10.1210/clinem/dgaa130
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958